Tinospora cordifolia

Tinospora Cordifolia (Guduchi / Giloy)

1. Identity and Botanical Description

Tinospora cordifolia, also known as guruchi, guduchi, amrita, or the heart-leaved moonseed, is a herbaceous vine of the family Menispermaceae native to South and Southeast Asia. Its full scientific name is Tinospora cordifolia (Willd.) Miers. Common names in English and various Indian languages include Amrita, Duyutige, Gado, Galo, Giloe, Giloya, Guduchi, Gulancha, Heartleaf moonseed, Teppatige, and Tinofend.

It is a deciduous woody climbing shrub found in India, China, and Africa, and is a member of the Menispermaceae family. It is widely distributed in tropical and subtropical regions, primarily found in India, Sri Lanka, and Myanmar. It is a large, deciduous, extensively spreading, climbing vine with several elongated twining branches. It gets its name "heart-leaved moonseed" from its heart-shaped leaves and reddish fruit.

The Tinospora genus, belonging to the Menispermaceae family, includes species such as T. cordifolia, T. sinensis, and T. crispa, which have long been utilized in traditional medicine. These species can be visually similar, and species confusion in commerce is a documented concern discussed further in the safety section.

The plant's pharmacological importance stems mostly from its root, stem, and leaf. In Sanskrit, it is known as "Guduchi" ("one that protects the whole body") or "Amrita" ("the nectar of immortality"), reflecting its association with vitality and longevity.

Common Preparations and Dosage Forms

Tinospora cordifolia is available in various forms for consumption, reflecting its long history of use. Common preparations include powders, capsules containing concentrated extracts, and fresh juice. Extracts are also widely available. In Ayurvedic practice, decoctions (kwath or kashaya) prepared from the stem are among the most traditional forms of administration. Clinical trials to support dosing are limited, with 300 mg of a standardized aqueous tinospora stem extract taken 3 times daily for up to 6 months reported in the literature.

2. Traditional and Historical Use

Ayurveda

T. cordifolia has a rich history of use in traditional systems of medicine, primarily Ayurveda. Ancient texts such as the Charaka Samhita and Sushruta Samhita describe its use in treating various ailments, including fever, diabetes, skin disorders, and digestive issues. It is often referred to as a Rasayana herb, a category of herbs in Ayurveda known for their rejuvenating and life-promoting properties. Various properties of T. cordifolia, described in ancient texts of Ayurveda, like Rasayana, Sangrahi, Balya, Agnideepana, Tridoshshamaka, Dahnashaka, Mehnashaka, Kasa-swasahara, Pandunashaka, Kamla-Kushta-Vataraktanashaka, Jwarhara, Krimihara, Prameha, Arshnashaka, Kricch-Hridroganashak, etc., are acquiring scientific validity through modern research adopting a "reverse pharmacological" approach.

In Ayurveda, Tinospora cordifolia has been used for over 2,000 years as a rasayana (rejuvenator) for immunity, diabetes, inflammation, and fever. It was traditionally administered to treat chronic fever (jwara), general debility, and to purify the blood.

Other Traditional Systems

It is also used in other traditional healing systems, such as Siddha and Unani medicine in India. Its medicinal properties have made it a staple in the traditional pharmacopeia of South Asian and Southeast Asian cultures.

In Indian folk traditions, decoctions of the stem were used for treating jaundice, urinary problems, and skin disorders. During epidemic outbreaks, including malaria and dengue fever, T. cordifolia was commonly given to strengthen immunity and reduce fever recurrence.

Among tribal groups, various preparations have been documented: the Baiga people living in the interior areas of Varanasi district in Uttar Pradesh prepared pills from the paste of the stem for fever; the tribals of Mumbai and its neighboring areas and the fishermen along the sea coast used the whole plant for fever, jaundice, chronic diarrhea, and periodic fever.

The utilization of T. cordifolia as an anti-diabetic has been recorded in the Ayurvedic Pharmacopoeia of India (Government of India, 2001).

3. Key Constituents and Active Compounds

The chemical constituents reported from this shrub belong to different classes, such as alkaloids, diterpenoid lactones, glycosides, steroids, sesquiterpenoids, phenolics, aliphatic compounds, and polysaccharides. Scientists have isolated various compounds from different parts of the plant, such as the root, stem, and bark. The plant extract chiefly contains glycosides, steroids, sesquiterpenoids, alkaloids, aliphatic compounds, fatty acids, essential oils, and polysaccharides.

Alkaloids

The alkaloid fraction is thought to have particular anti-diabetic activity. T. cordifolia contains numerous alkaloids including berberine, palmatine, tembetarine, magnoflorine, choline, tinosporin, isocolumbin, and tetrahydropalmatine; berberine and palmatine are found in surplus amounts. Additional alkaloids include jatrorrhizine and aporphine alkaloids, which have shown anti-cancer, anti-diabetes, anti-viral, anti-inflammatory, anti-psychiatric, and immunomodulatory action in experimental settings.

Diterpenoid Lactones and Glycosides

Active constituents also include diterpene compounds such as tinosporone, tinosporic acid, cordifolisides A to E, syringen, the yellow alkaloid berberine, giloin, crude giloinin, a glucosidal bitter principle, and polysaccharides including arabinogalactan polysaccharide. Furanolactone, diterpenoid lactones, and clerodane derivatives, including columbin, tinosporides, and tinosporin, have shown vasorelaxant, anti-inflammatory, anti-microbial, anti-hypertensive, and anti-viral biological actions.

Steroids and Polyphenols

The shoot part of T. cordifolia contains steroids such as β-sitosterol, δ-sitosterol, 20β-hydroxyecdysone, giloinsterol, Makisterone A, and ecdysterone. Picrotene and bergenin, possessing antioxidant properties, have also been reported from this plant.

Arabinogalactan Polysaccharide (G1-4A)

G1-4A, an acidic arabinogalactan derived from the stem of T. cordifolia, acts as a non-microbial TLR4 agonist, which leads to macrophage activation and induces B cell proliferation. This polysaccharide has been the subject of considerable mechanistic research and is described in detail in the immunology section below.

Biomarkers for Quality Control

Tinosporaside and berberine are identified as biomarkers for quality evaluation of this plant, even in extract form.

4. Mechanisms of Action

Immunomodulatory Mechanisms

The plant has been studied extensively for its immunomodulatory activities. The active principles of this plant cause significant increases in IgG antibodies in serum, along with macrophage activation.

An arabinogalactan polysaccharide, G1-4A, from the stem of Tinospora cordifolia has been investigated for protection against endotoxin-induced sepsis. There was 100% protection against lipopolysaccharide (LPS)-induced mortality in mice pretreated with G1-4A. To elucidate the mechanism of action, its effect on macrophages — the primary source of pro-inflammatory molecules — was evaluated. G1-4A was shown to bind to murine macrophages, leading to their activation, and reciprocally inhibited binding of LPS to macrophages.

Data from in vitro research demonstrated the upregulation of expression of TNF-α, IL-β, IL-6, IL-12, IL-10, and IFN-γ in macrophage cell lines after G1-4A treatment. Nitric oxide levels were also enhanced along with upregulation of NOS2 expression in murine macrophages. G1-4A treatment additionally upregulated the surface expression of MHC-II and CD-86 in macrophages. Using siRNA against TLR4 and MyD88, and anti-TLR4 blocking antibodies, researchers established that G1-4A activated macrophages through the classical TLR4-MyD88 dependent pathway.

Seven immunomodulatory active compounds belonging to different chemical classes have been isolated and characterized from T. cordifolia, indicating that the immunomodulatory activity may be attributed to a synergistic effect of a group of compounds.

Anti-Diabetic Mechanisms

A key marker of diabetes in cells, the insulin-dependent glucose transporter-4 (Glut-4), is overexpressed up to 5- and 4-fold by Tinospora cordifolia and palmatine respectively in differentiated myocytes. PPARα and PPARγ expressions were also positively modulated. Further, inhibitors of the insulin pathway prevented glucose uptake mediated by Tinospora cordifolia and palmatine, showing that the activity is majorly mediated through the insulin pathway.

It has been reported that daily administration of either ethanol or aqueous extracts of T. cordifolia decreases blood glucose levels and increases glucose tolerance in rodents. Tinospora cordifolia also inhibits the digestive enzymes α-glucosidase and α-amylase, reducing postprandial glucose absorption in a manner mechanistically similar to acarbose.

Antioxidant Mechanisms

Its diterpene glycoside cordifolide A and furanoid compounds scavenge reactive oxygen species and upregulate endogenous antioxidant defenses including superoxide dismutase.

Anti-Tuberculosis Mechanisms (Preclinical)

G1-4A treatment of Mycobacterium tuberculosis-infected macrophages significantly induced the surface expression of MHC-II and CD-86 molecules, secretion of proinflammatory cytokines (TNF-α, IL-β, IL-6, IL-12, IFN-γ), and nitric oxide, leading to reduced intracellular survival of both drug-sensitive and multi-drug resistant strains of MTB, which was partially attributed to G1-4A-induced NO production in a TLR4-MyD88 dependent manner. These findings are preclinical only.

5. Scientific Evidence by Area of Use

The overall scientific evidence base for T. cordifolia consists predominantly of in vitro studies, animal models, and a small number of human clinical trials. Experiments have examined its antineoplastic, antioxidant, hepatoprotective, hypolipidemic, and immunologic properties; however, few clinical trials exist. Although used in Ayurveda over centuries in the belief that Tinospora has medicinal properties, there is no evidence from reviews of clinical research to indicate that it has any effect. The following subsections characterize the evidence that does exist.

5.1 Allergic Rhinitis

The most robustly designed human trial identified in the literature evaluated T. cordifolia for allergic rhinitis. The efficacy of Tinospora cordifolia (TC) extract in patients of allergic rhinitis was assessed in a randomized, double-blind, placebo-controlled trial in which 75 patients were randomly given either TC or placebo for 8 weeks. With TC treatment, 100% relief was reported from sneezing in 83% of patients, in 69% from nasal discharge, in 61% from nasal obstruction, and in 71% from nasal pruritus. In the placebo group, there was no relief in 79% from sneezing, in 84.8% from nasal discharge, in 83% from nasal obstruction, and in 88% from nasal pruritus. The difference between the TC and placebo groups was highly significant. A small, eight-week clinical trial in hay fever patients suggested that Tinospora cordifolia is generally well-tolerated, with side effects that included nasal pain and headache. While these results are promising, this trial has not been independently replicated at larger scale and the evidence must therefore be considered preliminary.

5.2 Immunomodulation and Wound Healing (Diabetic Foot Ulcers)

A prospective double-blind randomized controlled study lasting over 18 months was conducted in 50 patients with diabetic foot ulcers. Researchers evaluated the role of generalized immunomodulation in diabetic ulcers by using Tinospora cordifolia as an adjuvant therapy and studied its influence on parameters of healing, bacterial eradication, and polymorphonuclear phagocytosis. Diabetic patients with foot ulcers on T. cordifolia as adjuvant therapy showed significantly better final outcomes with improvement in wound healing. Reduced debridements and improved phagocytosis were statistically significant, indicating beneficial effects of immunomodulation for ulcer healing. This is one of the few published randomized controlled trials in humans; the small sample size and single-center design limit its generalizability.

5.3 Diabetes and Blood Sugar Regulation

Traditionally, Tinospora cordifolia is commonly used in the treatment of diabetes and obesity, and has been evaluated for its anti-diabetic and anti-obese potency in experimental animal models. T. cordifolia has been reported for the reduction of oxidative stress, modulation of carbohydrate metabolism, hypoglycemic activity, and modulation of multiple proteins involved in diabetes via experimental and computational approaches. Human clinical evidence for glycemic control as a primary endpoint is very limited. Preclinical findings are supported by mechanistic studies (see Section 4), but no large-scale, adequately powered randomized controlled trials in humans have been published as of the current literature review.

5.4 COVID-19 (Mild Disease)

One published clinical report provided evidence of Tinospora cordifolia (TC) group showing immunomodulatory effects in a randomized open-label three-armed study examining herbal extracts in mild COVID-19 patients. The trial was registered with the Clinical Trials Database — India (ICMR-NIMS), CTRI/2020/09/028043. This study was open-label, included a limited population with mild disease, and was conducted within a multi-arm design; evidence from this single trial is preliminary.

5.5 Dengue Fever

T. cordifolia is one of the highly explored plants at the local level for its effective anti-dengue formulations, and researchers have aimed to critically assess the data available on its anti-dengue therapeutic use. Berberine is considered the principal phytocompound of T. cordifolia responsible for its anti-dengue potential. The anti-dengue effect is proposed to be rendered by suppressing the initiation of the "cytokine storm," vascular leakage, and inhibition of various structural and NS proteins. Further in-silico and clinical studies are needed so that a stable, safe, and efficacious anti-dengue drug can be developed. Evidence for clinical benefit in dengue remains at the level of preliminary clinical data, in vitro, and in silico studies.

5.6 Anticancer Activity

Researchers have shown phenotypic and functional maturation of bone marrow-derived dendritic cells (BMDC) by G1-4A, an arabinogalactan derived from Tinospora cordifolia, and in follow-up studies have observed a several-fold increase in the killing of tumor cells by BMDCs matured in the presence of G1-4A. An in vitro study found an increase in prostate cancer cells; therefore, tinospora probably should not be consumed in this condition until further studies are conducted. All anti-cancer evidence is currently in vitro or animal-based; no human clinical trials for any cancer indication have been published.

5.7 Other Studied Areas

Potential medicinal properties reported by scientific research include anti-diabetic, antipyretic, antispasmodic, anti-inflammatory, anti-arthritic, antioxidant, anti-allergic, anti-stress, anti-leprotic, antimalarial, hepatoprotective, immunomodulatory, and anti-neoplastic activities. The evidence base for most of these remains at the preclinical (animal or in vitro) level. There have been a few clinical trials on Tinospora cordifolia, but none of them have examined its impact on cognitive function or brain health.

6. Body Systems Associated

• Immune System: The most extensively studied pharmacological domain; both humoral (IgG elevation) and cellular immunity (macrophage activation, NK cells, dendritic cells) have been implicated in preclinical studies.
• Metabolic / Endocrine System: T. cordifolia has been used to treat fevers, jaundice, diabetes, dysentery, urinary infections, and skin diseases. Blood glucose modulation is supported by both animal studies and mechanistic in vitro research.
• Hepatic System: Paradoxically described in both traditional use as a hepatoprotective agent and in modern literature as a clinically documented cause of herb-induced liver injury (see Safety, Section 8).
• Respiratory / Allergy: Evaluated in one human RCT for allergic rhinitis with positive preliminary results.
• Musculoskeletal / Inflammatory: T. cordifolia is used in the Indian Ayurvedic system of medicine for the treatment of jaundice, diabetes, and rheumatoid arthritis, and is also used as an immunostimulant.
• Oncology (preclinical): G1-4A polysaccharide and other constituents have been studied in vitro for effects on tumor cell killing.

7. Dosage as Reported in Studies

Reported dosages in published clinical and experimental sources vary considerably by preparation type and indication:

• Clinical trials to support dosing are limited, with 300 mg of a standardized aqueous tinospora stem extract taken 3 times daily (i.e., 900 mg/day total) for up to 6 months reported in the literature.
• In at least one documented case of herb-induced liver injury, the patient was taking 900 mg of Tinospora cordifolia extract (stem) daily as a single tablet for immune support.
• In an animal study of hepatoprotective effects against lead toxicity, aqueous stem extract and aqueous leaf extract were both administered at 400 mg/kg body weight orally, together with lead nitrate at 5 mg/kg body weight intraperitoneally for 30 days, and were associated with increased activities of SOD and CAT and decreased liver enzyme levels. This dose is in rodents and cannot be directly translated to humans.
• In a glucose uptake cell study, serially solvent-extracted T. cordifolia stems, particularly water, ethanol, and methanol extracts, showed glucose uptake activity stimulated in a dose-dependent manner at dosages of 1–100 μg in the in vitro model used.

There is not enough reliable information to know what an appropriate dose of Tinospora cordifolia might be across indications.

8. Safety Considerations and Drug Interactions

Herb-Induced Liver Injury (HILI) — The Most Serious Known Risk

T. cordifolia supplement usage is the highest reported causative agent of herb-induced liver injury in India. Cases of liver injury from Tinospora cordifolia have ranged in severity from minimally symptomatic elevations in serum aminotransferase levels to cases of mild hepatitis resolving rapidly upon stopping, to severe hepatitis including acute liver failure leading to fatalities.

In addition to publications of more than 50 cases of T. cordifolia-induced liver injury, there are at least 7 published cases attributed to T. crispa. The injury from both species was typically hepatocellular with ALT and AST values of 10 to 50 times the upper limit of normal (500 to 3000 U/L), with minimal alkaline phosphatase and GGT elevations and variable degrees of hyperbilirubinemia. The latency to onset ranged from a few weeks to 6 months. Immune allergic symptoms such as fever and rash occurred but were not common, while autoantibodies were frequent and sometimes accompanied by hyperglobulinemia and autoimmune features on liver biopsy.

Several fatal cases with submassive hepatic necrosis have been described, most often in patients with pre-existing liver disease.

The liver injury appears to be idiosyncratic and possibly immune-mediated. Further research on the precise mechanism of its hepatotoxicity is warranted.

According to published case series, Tinospora cordifolia may stimulate the immune system to reveal underlying autoimmune liver disease. It may also induce an immune response to a reactive metabolite acting as a hapten, causing an immunoallergic type of herb-induced liver injury. In one published case series, six patients presented with symptoms of acute hepatitis after consumption of Tinospora cordifolia; the average duration of consumption was 90 days. These patients had autoimmune-like injury features on biopsy, and most had underlying chronic liver disease of likely autoimmune etiology. One patient died of liver failure, whereas the others recovered fully.

While some observers contested that patients may have mistakenly self-medicated with T. crispa (a visually similar species), collected plant samples and commercial preparations were subjected to high-performance thin layer chromatography phytochemical analysis and DNA barcoding studies for the confirmation of genus and species. The four plant part samples, including stems and leaves, were also analyzed by a botanist for characteristic morphological and microscopic features. Investigation showed the toxicity to result directly from compounds in the plant itself, such as furano-diterpenoids.

Gastrointestinal Side Effects

Limited clinical studies reveal few adverse reactions; gastrointestinal symptoms (anorexia, nausea, vomiting) have been reported.

Blood Sugar Interactions

Tinospora cordifolia might lower blood sugar levels. It should be used cautiously in diabetes, with blood sugar levels monitored, as the doses of diabetes medications might need to be adjusted. Tinospora cordifolia can lower blood sugar levels and may therefore interact with anti-diabetic medications such as glimepiride, glyburide, insulin, pioglitazone, rosiglitazone, and glipizide.

Immunosuppressant Interactions

Tinospora cordifolia may cause the immune system to become more active, thus increasing the symptoms of autoimmune diseases such as multiple sclerosis, lupus, and rheumatoid arthritis. It interacts with immunosuppressants including cyclosporine, azathioprine, basiliximab, corticosteroids, prednisone, tacrolimus, sirolimus, and others.

Autoimmune Disease Caution

Tinospora cordifolia might cause the immune system to become more active, and this could increase the symptoms of autoimmune diseases such as multiple sclerosis, lupus, and rheumatoid arthritis. In individuals with these conditions, it is best to avoid use.

Pregnancy and Lactation

Information regarding safety and efficacy during pregnancy and lactation is lacking.

Surgery

Tinospora cordifolia might affect blood sugar levels and this might interfere with blood sugar control during and after surgery.

Cytochrome P450 Interactions

Tinospora cordifolia might change how quickly the liver breaks down certain medications, which could change the effects and side effects of those medications.

Prostate Cancer

An in vitro study found an increase in prostate cancer cells; therefore, tinospora probably should not be consumed in this condition until further studies are conducted.

References

• Hemalatha R, et al. "The chemical constituents and diverse pharmacological importance of Tinospora cordifolia." Heliyon, PMC6827274, 2019.
• Hemalatha R, et al. "The chemical constituents and diverse pharmacological importance of Tinospora cordifolia." ScienceDirect / Heliyon, 2019.
• Upadhyay AK, et al. "Tinospora cordifolia (Willd.) Hook. f. and Thoms. (Guduchi) – validation of the Ayurvedic pharmacology through experimental and clinical studies." Ancient Science of Life, PMC2924974, 2010.
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — Tinospora. National Institute of Diabetes and Digestive and Kidney Diseases (NIH), updated June 2025.
• Wikipedia: Tinospora cordifolia.
• Nair PK, et al. "Immunomodulatory active compounds from Tinospora cordifolia." J Ethnopharmacol, PubMed 22472109, 2012.
• Bairy I, et al. "Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study." Indian J Med Sci, PubMed 17558098, 2007.
• Ahsan R, et al. "Therapeutic Application, Phytoactives and Pharmacology of Tinospora cordifolia: An Evocative Review." PMC10073789, 2023.
• Adhatoda vasica and Tinospora cordifolia extracts ameliorate clinical and molecular markers in mild COVID-19 patients: a randomized open-label three-armed study. PMC10696694, 2023.
• Patel MB, Mishra S. "Anti-diabetic property of Tinospora cordifolia and its active compound is mediated through the expression of Glut-4 in L6 myotubes." Phytomedicine, ScienceDirect, 2012.
• Badar VA, et al. "Efficacy of Tinospora cordifolia in allergic rhinitis." J Ethnopharmacol, PubMed 15619563, 2005.
• Gupta PK, et al. "G1-4A, an immunomodulatory polysaccharide from Tinospora cordifolia, modulates macrophage responses and protects mice against lipopolysaccharide induced endotoxic shock." Int Immunopharmacol, PubMed 17673153, 2007.
• Shukla M, et al. "G1-4A, a Polysaccharide from Tinospora cordifolia Inhibits the Survival of Mycobacterium tuberculosis by Modulating Host Immune Responses in TLR4 Dependent Manner." PLOS ONE, PMC4858241, 2016.
• Gupta PK, Rajan MGR, Kulkarni S. "Activation of murine macrophages by G1-4A, a polysaccharide from Tinospora cordifolia, in TLR4/MyD88 dependent manner." Int Immunopharmacol, PubMed 28667885, 2017.
• Nnamani I, et al. "Tinospora cordifolia (Guduchi/Giloy)-Induced Liver Injury: A Case Review." Cureus, PMC10238282, 2023.
• Nagral A, et al. "Herb-induced Liver Injury — A Guide to Approach. Lessons from the Tinospora cordifolia (Giloy) Case Series Story." PMC10025683, 2023.
• Sherazi SA, et al. "Herbal- and Dietary-Supplement-Induced Liver Injury: A Review of the Recent Literature." MDPI Livers, 2024.
• Tinospora cordifolia-associated hepatotoxicity has been scientifically misconstrued, in haste. PubMed 35852310, 2022.
• Nandan A, et al. "Deciphering the mechanism of Tinospora cordifolia extract on Th17 cells through in-depth transcriptomic profiling and in silico analysis." Front Pharmacol, 2023.
• Tinospora cordifolia — Overview. ScienceDirect Topics.
• Tinospora Uses, Benefits & Dosage. Drugs.com, updated February 2026.
• Tinospora Cordifolia & Your Brain. Alzheimer's Drug Discovery Foundation — Cognitive Vitality, 2019.
• Krupanidhi S, et al. "Screening of phytochemical compounds of Tinospora cordifolia for their inhibitory activity on SARS-CoV-2: an in silico study." PMC7441789, 2020.
• Gupta B, et al. "Anti-dengue therapeutic potential of Tinospora cordifolia and its bioactives." J Ethnopharmacol, PubMed 38679398, 2024.
• Pharmacognostic evaluation of Tinospora cordifolia. Indian Journal of Traditional Knowledge, NISCPR, 2014.